

Ref. No.: LASA/SE/24-25/011

Thursday, May 30, 2024

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir/Madam,

Sub. : **Outcome of Board Meeting held today i.e. May 30, 2024**

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 8.00 p.m. and concluded at 10.45 p.m. inter- alia have considered and approved the following:

1. The statement of Audited Financial Results of the Company for the quarter and the financial year ended on March 31, 2024
2. A copy of the statement of audited Financial Results, Cash Flow statement along with Audited Report submitted by the Statutory Auditors of the Company is attached herewith.

The above information is also available on the company's website at www.lasalabs.com and on the website of the stock Exchange at www.bseindia.com and www.nseindia.com.

FOR LASA SUPERGENERICS LIMITED

MITTI JAIN
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO.33681



LASA SUPERGENERICS LIMITED

Corporate Office : 506, 507, 5th Floor, Midas, Sahar Plaza, Andheri Kurla Road, Andheri (E),
Mumbai - 400 059, Maharashtra, INDIA
Email : info@lasalabs.com • Website : www.lasalabs.com

Ref. No.: LASA/SE/24-25/012

Thursday, May 30 2024

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Dear Sir/Madam,

Sub.: Declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In Compliance with Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification no. SEBI/LAD-NRO/GN/2016- 17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby state that the Statutory Auditors of the Company M/s Gupta Rustagi & Co., Chartered Accountants (FRN: 128701W) have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2024.

You are requested to take the same on record.

THANKING YOU
YOURS SINCERELY
FOR LASA SUPERGENERICS LIMITED

MITTI JAIN
COMPANY SECRETARY AND COMPLIANCE OFFICER



Statement of Audited Financial Results for Quarter and Year ended 31st March, 2024

(Rs in Lakhs)

Particulars	Quarter ended			Year ended	
	31.03.2024 (Audited)	31.12.2023 (Unaudited)	31.03.2023 (Audited)	31.03.2024 (Audited)	31.03.2023 (Audited)
a. Revenue from Operations	2,281.63	2,666.01	3,532.29	10,433.50	12,956.78
b. Other Income	0.79	0.36	93.15	9.93	180.46
Total Income	2,282.41	2,666.37	3,625.44	10,443.43	13,137.24
2. Expenses					
a. Cost of Materials consumed	1,903.64	1,838.68	2,385.66	7,928.17	11,012.14
b. Cost of Traded Goods	-	-	-	-	-
c. Change in Inventories of Finished Goods, Work-in-Progress	(56.06)	154.04	149.87	(406.41)	(400.71)
d. Employee benefits expenses	150.84	155.49	145.70	634.18	736.81
e. Finance costs	56.02	44.10	41.47	193.19	416.05
f. Depreciation & amortizations expenses	266.13	267.96	416.99	1,067.26	1,341.90
g. Other Expenses	681.29	412.52	417.12	2,060.98	2,267.90
Total Expenses (a to g)	3,001.85	2,872.78	3,556.80	11,477.37	15,374.09
Exceptional Items	877.32	-	1,989.66	877.32	1,989.66
3. Profit / (Loss) before tax (1-2)	(1,596.75)	(206.41)	(1,921.03)	(1,911.25)	(4,226.51)
4. Tax expense					
Current Tax	-	-	-	-	-
Deferred Tax	(66.74)	(60.59)	(420.94)	261.81	(368.77)
Short / Excess income tax provision for earlier years	-	-	-	-	4.33
5. Net Profit / (Loss) after tax (3-4)	(1,530.01)	(145.82)	(1,500.08)	(2,173.06)	(3,862.07)
6. Other Comprehensive Income					
Items that will not be reclassified into Profit or Loss					
- Remeasurement of Defined Benefit Plans (Net of tax)	11.54	-	3.91	11.54	3.91
7. Total Comprehensive Income for the year (after tax) (5+6)	(1,518.47)	(145.82)	(1,496.17)	(2,161.52)	(3,858.15)
8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)	5,010.12	5,010.12	5,010.12	5,010.12	5,010.12
9. Earnings per Equity Share (of Rs. 10/- each)					
(a) Basic	(3.05)	(0.29)	(2.99)	(4.34)	(7.71)
(b) Diluted	(3.05)	(0.29)	(2.99)	(4.34)	(7.71)

Notes :

- The Above Financial Results were reviewed by the audit committee of the board on **30th May 2024** and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The auditors report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.
- (i) The Company has paid advances Rs.470 Lacs to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021 on behalf of Omkar Speciality Chemicals Ltd against which material was supposed to be supplied by OSCL, in the meantime OSCL admitted into CIRP, Company have filed claim with Resolution Professional status of which is still under inspection.. The said advance is forming part of Note 12 - Other Current Assets- Advance paid to Suppliers.
(ii) Amount receivable of Rs.848.54 lacs from Vivid Finance & Holdings Ltd is forming part of Note 12 - Other Current Assets- Advance paid to others. The same is also outstanding since long and a dispute is there regarding the recoverability of the said amount, however, the Company is making best possible efforts to recover the same.
Provision for Doubtful Advances is created at 50% during Quarter 4 FY 2023-24, for both advances (i) & (ii)
- Capital Work in progress amounting to Rs. 464.47 Lacs on which there is no progress and in absence of any decision regarding the treatment and usability of the same, the Company has considered 50% impairment on the same and provided for the same.
- Exceptional Items is towards Provision for Doubtful Advances (as per point 2) & Impairment of Capital WIP (as per point 3)
- Finance Cost for FY 23-24, includes ECB interest Rs.191.41 lakhs provision for Interest on alleged ECB Loan (Which is Disputed) as per IND AS
- The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segment information is not applicable.
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.



For Lasa Supergenerics Ltd




Omkar Herlekar
Chairman & Managing Director



(DIN No. 01587154)

Place : Mumbai
Date : 30th May 2024

LASA SUPERGENERICS LIMITED			
CIN: L24233MH2016PLC274202			
Balance Sheet as at March 31, 2024			
(Rs. In Lakhs)			
Particulars	Note No.	As at 31 March 2024	As at 31 March 2023
ASSETS			
Non-current assets			
Property, Plant and Equipment	3	8,381.90	8,813.47
Capital Work in Progress	3	250.88	464.47
Intangible assets	3	2,594.17	3,082.35
<u>Financial Assets</u>			
Non Current Investments	4	-	38.71
Deposits	5	70.98	64.44
		11,297.93	12,463.45
Current assets			
Inventories	6	1,904.34	1,390.30
<u>Financial Assets</u>			
Trade receivables	7	358.69	247.78
Cash and cash equivalents	8	60.86	79.95
Bank balances other than cash & cash equivalents	9	88.77	159.07
Loans	10	5.00	5.00
Other financial Assets			
Other current assets	11	1,371.28	2,039.94
		3,788.94	3,922.05
		15,086.87	16,385.49
EQUITY AND LIABILITIES			
EQUITY			
Equity Share capital	12	5,010.12	5,010.12
Other Equity	13	4,657.50	6,818.47
		9,667.63	11,828.59
LIABILITIES			
Non-current liabilities			
<u>Financial Liabilities</u>			
Non Current Borrowings		-	-
Provisions	14	47.40	60.60
Deferred Tax Liabilities	15	484.80	223.53
		532.20	284.12
<u>Current liabilities</u>			
<u>Financial Liabilities</u>			
Current Borrowings	16	2,207.62	2,176.99
<u>Trade payables:</u>			
Total outstanding dues of micro enterprises and small enterprises	17	648.50	156.90
Total outstanding dues of creditors other than micro enterprises and small enterprises		756.86	785.84
Other financial liabilities		-	-
Other current liabilities	18	147.98	138.81
Provisions	19	1,126.09	1,014.25
Current tax liabilities (net)			
		4,887.05	4,272.79
		15,086.87	16,385.49
For Gupta Rustagi & Co.		For Lasa Supergenerics Limited	
Chartered Accountants			
Firm Registration No.: 128701W			
SD/-		Omkar Herlekar	
Niraj Gupta		(Chairman & Managing Director)	
(Partner)		DIN:01587154	
M.No.: 100808			
Place : Mumbai			
Date : 30th May 2024			

LASA SUPERGENERICS LIMITED CIN: L24233MH2016PLC274202 Statement of Cash flows for the year ended March 31, 2024		(Rs. In Lakhs)
Particulars	Year ended 31 March 2024	Year ended 31 March 2023
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	(1,911.25)	(2,236.85)
Adjustments for		
Depreciation and Amortisation Expense	1,067.26	1,341.90
Finance Costs	193.19	416.05
Interest income & gain on sale of shares	(17.36)	(180.46)
Remeasurement of employee defined benefit obligation	11.54	5.05
Adjustment for Exceptional Items (Non-Operating Activity)	232.23	(1,989.66)
Provision for doubtful debts and advances (net)	(645.08)	-
Operating profit before working capital changes	(1,069.47)	(2,643.97)
Working capital adjustments :-		
(Increase) / Decrease in Trade and Other Receivables	534.17	1,607.98
(Increase) / Decrease in Inventories	(514.04)	(240.53)
(Increase) / Decrease in Loans	(6.54)	(1.18)
(Increase) / Decrease in Other Current Assets	668.65	(142.29)
Increase / (Decrease) in Trade and Other Payables	462.61	(748.29)
Increase / (Decrease) in Provisions	98.64	410.27
Increase / (Decrease) in Current Borrowings	30.64	-
Increase / (Decrease) in Financial Liabilities	-	159.90
Increase / (Decrease) in Other Current Liabilities	9.17	(127.58)
Cash generated from / (used in) operations	213.82	(1,725.71)
Direct taxes paid (Net of Refunds)	-	(4.33)
Net cash (used in) / from generated from operating activities	213.82	(1,730.04)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment and intangible assets (including capital work-in-progress and capital advances)	66.08	483.29
Impairment of Fixed Assets (CWIP) (No Cash Flow)	(232.23)	
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	109.01	455.73
Interest received	17.36	180.47
Net cash (used in) / generated from investing activities	(39.78)	1,119.49
C. CASH FLOW FROM FINANCING ACTIVITIES		
Interest paid	(193.19)	(416.06)
Net cash (used in) / from financing activities	(193.19)	(416.06)
Net decrease in cash and cash equivalents (A+B+C)	(19.14)	(1,026.61)
Cash and cash equivalents at the beginning of the year	79.95	1,106.56
Cash and cash equivalents at the end of the year	60.81	79.95
Components of cash and cash equivalents considered only for the purpose of cash flow statement		
In bank current accounts in Indian rupees	50.73	74.62
Cash on hand	10.08	5.33
	60.81	79.95
For Gupta Rustagi & Co. Chartered Accountants Firm Registration No.: 128701W	For Lasa Supergenerics Limited	
SD/- Niraj Gupta (Partner) M.No.: 100808	 Omkar Herlekar (Chairman & Managing Director) DIN:01587154	
		
Place : Mumbai Date : 30th May 2024		



Independent Auditor's Report on the Quarterly and Year to Date Audited Financial Results of the Company pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Lasa Supergenerics Limited
Report on the Audit of the Standalone Financial Results

Opinion

1. We have audited the accompanying statement of quarterly and the year-to-date financial results of **Lasa Supergenerics Limited** ('the Company') for the quarter ended March 31, 2024, and for the year ended March 31, 2024 ('the statement'), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing Regulations).
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - i. Is presented in accordance with the requirements of the Listing Regulations in this regard; and
 - ii. As described in the Basis for Opinion paragraph below, gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2024, and for the year ended March 31, 2024.

Basis of Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143 (10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Statements" section of our report. We are independent of the Company in accordance with the code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.



Emphasis of Matter

4. We draw attention to Note 2 of the Financial Results wherein:
- (i) The Company has paid advances Rs.470 Lacs to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021 on behalf of Omkar Speciality Chemicals Ltd (OSCL) against which material was supposed to be supplied by OSCL, in the meantime OSCL admitted into CIRP, Company have filed claim with Resolution Professional status of which has been admitted. The said advance is forming part of Note 12 - Other Current Assets- Advance paid to Suppliers.
- (ii) Amount receivable of Rs.848.54 Lacs from Vivid Finance & Holdings Ltd is forming part of Note 12 - Other Current Assets- Advance paid to Suppliers. The same is also outstanding since long and a dispute is there regarding the recoverability of the said amount, however, Company is making best possible efforts to recover the same.
- Provision for Doubtful Advances is created at 50% during Quarter 4 FY 2023-24, for both advances (i) & (ii). We are of the opinion that the Company has conservatively provided for 50% of the outstanding amount. However, chances of recoverability of the same remains doubtful as both the matters are sub-judice.
5. As mentioned in Note 3, Capital Work in progress amounting to Rs. 464.47 Lacs on which there is no progress and in absence of any decision regarding the treatment and usability of the same, the Company has considered 50% impairment on the same and provided for the same.
6. The bank balance confirmation of bank accounts having book balance of Rupees 4.54 Lacs as on 31-03-2024 & Fixed deposits confirmation of book balance of Rupees 10.89 Lacs as on 31-03-2024 could not be obtained as these accounts and fixed deposits are in dormant status. Had balance confirmations been received, there may have been additional adjustments required to the financial result which are not determinable, at this stage.

Our opinion is not modified in respect of the above matters.

Management's Responsibility for the Standalone Financial Statements

7. The Statement has been prepared on the basis of standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribes under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies, making judgements and estimates that are reasonable and prudent; and the design; implementation and



maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

8. In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
9. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

10. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is high level of assurance but is not a guarantee that an audit conducted in accordance with SA's will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.
11. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedure responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to the financial statements in place and operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of the accounting estimates and related disclosure made by the Board of Directors.
 - Conclude of the appropriateness of the Board of Directors' use of going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement, or if such disclosures are inadequate,



to modify our opinion. Our conclusions given in a qualification no. 1 are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represents the underlying transactions and events in a manner that achieves fair presentation.
12. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
13. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

14. The Statement includes the results for the quarter ended March 31, 2024 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to limited review by us, as required under the listing Regulations.

For **Gupta Rustagi & Co.**

Chartered Accountants

ICAI FRN: 128701W



Niraj Gupta

Partner

Mem.no.100808

UDIN : 24100808BKDHXQ3614

Place: Mumbai

Date: 30th May, 2024